Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01ZYG
|
||||
| Former ID |
DAP000385
|
||||
| Drug Name |
Alemtuzumab
|
||||
| Synonyms |
Campath (TN); MabCampath (TN); Campath-1H (TN)
|
||||
| Drug Type |
Antibody
|
||||
| Therapeutic Class |
Anticancer Agents
|
||||
| Company |
Bayer Schering Pharma
|
||||
| Formula |
C6468H10066N1732O2005S40
|
||||
| CAS Number |
CAS 216503-57-0
|
||||
| SuperDrug ATC ID |
L01XC04
|
||||
| Target and Pathway | |||||
| Target(s) | CAMPATH-1 antigen | Target Info | [537198], [537391], [537403], [537504] | ||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| References | |||||
| Ref 532651 | 2013 FDA drug approvals. Nat Rev Drug Discov. 2014 Feb;13(2):85-9. | ||||
| Ref 537129 | New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21. | ||||
| Ref 541850 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6770). | ||||
| Ref 537198 | Targeted therapy for chronic lymphocytic leukemia. Target Oncol. 2009 Jan;4(1):11-21. Epub 2009 Jan 27. | ||||
| Ref 537391 | CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies. Leuk Lymphoma. 2009 Jun;50(6):1010-6. | ||||
| Ref 537403 | Clinical evaluation of busulfan, cladribine and alemtuzumab as reduced intensity conditioning for stem cell transplantation. Ann Transplant. 2009 Apr-Jun;14(2):7-12. | ||||
| Ref 537504 | Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. J Transl Med. 2009 Jun 19;7:49. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.